Nuvilex Provides Shareholder Update on Cancer and Diabetes Programs
December 16 2014 - 9:30AM
InvestorsHub NewsWire
SILVER SPRING, MD -
December 16, 2014 - InvestorsHub NewsWire - Nuvilex, Inc.
(OTCQB:
NVLX), a clinical-stage biotechnology company providing cell
solutions for the treatment of diseases, today announced a
shareholder update on the Company’s cancer and diabetes programs
utilizing its Cell-in-a-Box® cellulose-based live cell
encapsulation technology.
• The first
preclinical study by TD2 in the U.S. that deals with the
effectiveness of Nuvilex’s pancreatic cancer treatment on the
accumulation of malignant ascites fluid that is often associated
with the growth of abdominal cancers, including pancreatic cancer,
has been completed and positive results were obtained.
• Nuvilex has commenced the development of a clinical
protocol for the planned Phase 2b clinical trial in pancreatic
cancer.
• Applications have been submitted to drug regulatory
authorities in the U.S., Europe and Australia to obtain Orphan Drug
status for Nuvilex’s pancreatic cancer treatment that combines
Cell-in-a-Box® with low doses of the anticancer prodrug
ifosfamide.
• Contracts have been executed with major institutions that
will permit the development of a diabetes treatment that combines
Cell-in-a-Box® with insulin-producing cells, and a
Diabetes Consortium has been established to facilitate this
important research.
• The live cell encapsulation facility in Thailand, where the
Cell-in-a-Box® encapsulation will be done, has now
officially opened and is an extremely important development as this
facility is essential for all of Nuvilex’s efforts in developing
treatments for cancer and diabetes.
• Rapid progress is being achieved at the University of
Northern Colorado in the pursuit of treatments for cancer that will
combine cannabinoid-like compounds with the
Cell-in-a-Box® technology.
“This is truly an
exciting, important time for Nuvilex, and I wish to extend my
sincere appreciation to our longstanding shareholders for their
continued support during this transformational period of our
growth,” commented Kenneth L. Waggoner, Chief Executive Officer of
Nuvilex.
An extensive update on Nuvilex’s programs has been prepared and can
be reviewed on the Nuvilex website at: http://www.nuvilex.com/shareholder-update-on-recent-activities-in-the-areas-of-cancer-and-diabetes
About Nuvilex
Nuvilex (OTCQB:
NVLX) is a clinical stage biotechnology company focused on
developing and preparing to commercialize treatments for cancer and
diabetes based upon a proprietary cellulose-based live cell
encapsulation technology known as Cell-in-a-Box®. This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
Nuvilex's treatment for pancreatic cancer involves the well-known
anticancer prodrug ifosfamide, together with encapsulated live
cells, which convert ifosfamide into its active or "cancer-killing"
form. In addition, Nuvilex is working towards improving the quality
of life for patients with advanced pancreatic cancer and on
treatments for other types of solid cancerous tumors. Nuvilex is
also developing treatments for cancer based upon chemical
constituents of marijuana known as cannabinoids. Nuvilex is
examining ways to exploit the benefits of Cell-in-a-Box®
technology in optimizing the anticancer effectiveness of
cannabinoids, while minimizing or outright eliminating the
debilitating side effects usually associated with cancer
treatments. This provides Nuvilex a unique opportunity to develop
“green” approaches to fighting deadly cancers, such as those of the
pancreas, brain and breast, which affect hundreds of thousands of
individuals worldwide every year.
Safe Harbor
This press release may contain forward-looking statements regarding
Nuvilex and its future events and results that involve inherent
risks and uncertainties. The words "anticipate," "believe,"
"estimate," "expect," "intend," "plan" and similar expressions, as
they relate to Nuvilex or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of Nuvilex, could cause actual results to differ
materially from those set forth in the forward-looking statements.
They include Nuvilex's ability to continue as a going concern,
delays or unsuccessful results in clinical trials or flaws or
defects regarding its product candidates, changes in relevant
legislation or regulatory requirements, uncertainty of protection
of Nuvilex's intellectual property and Nuvilex's continued ability
to raise capital. Nuvilex does not assume any obligation to
update any of these forward-looking statements.
More information about Nuvilex can be found at www.nuvilex.com. It can also be obtained by contacting
Investor Relations.
Investor Relations Contacts:
Clare Matschullat
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 106
cmatschullat@bplifescience.com